These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37644825)

  • 1. Revealing metastatic castration-resistant prostate cancer master regulator through lncRNAs-centered regulatory network.
    Ferraz RS; Cavalcante JVF; Magalhães L; Ribeiro-Dos-Santos Â; Dalmolin RJS
    Cancer Med; 2023 Sep; 12(18):19279-19290. PubMed ID: 37644825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
    Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
    Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.
    Zhang A; Zhao JC; Kim J; Fong KW; Yang YA; Chakravarti D; Mo YY; Yu J
    Cell Rep; 2015 Oct; 13(1):209-221. PubMed ID: 26411689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.
    Shih TC; Liu R; Wu CT; Li X; Xiao W; Deng X; Kiss S; Wang T; Chen XJ; Carney R; Kung HJ; Duan Y; Ghosh PM; Lam KS
    Clin Cancer Res; 2018 Sep; 24(17):4319-4331. PubMed ID: 29666302
    [No Abstract]   [Full Text] [Related]  

  • 5. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
    Colditz J; Rupf B; Maiwald C; Baniahmad A
    Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases.
    Sattari M; Kohvakka A; Moradi E; Rauhala H; Urhonen H; Isaacs WB; Nykter M; Murtola TJ; Tammela TLJ; Latonen L; Bova GS; Kesseli J; Visakorpi T
    Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37140987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program.
    Parolia A; Venalainen E; Xue H; Mather R; Lin D; Wu R; Pucci P; Rogalski J; Evans JR; Feng F; Collins CC; Wang Y; Crea F
    Mol Oncol; 2019 May; 13(5):1121-1136. PubMed ID: 30776192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance.
    Cai Z; Wu Y; Li Y; Ren J; Wang L
    Aging (Albany NY); 2018 Dec; 10(12):3702-3712. PubMed ID: 30513511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth.
    Ta HQ; Whitworth H; Yin Y; Conaway M; Frierson HF; Campbell MJ; Raj GV; Gioeli D
    Mol Cancer; 2019 Jun; 18(1):113. PubMed ID: 31253147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
    Sung YY; Cheung E
    Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells.
    Misawa A; Takayama K; Urano T; Inoue S
    J Biol Chem; 2016 Aug; 291(34):17861-80. PubMed ID: 27342777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
    Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
    Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
    Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
    Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
    Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.